Immuneai-CMV (Phase-I): Precision Phenotyping Reveals Heterogeneous CMV–GVHD Trade-Offs Following Allogeneic HCT (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #763; 570; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); "Introduction Post-transplant cyclophosphamide (PTCy) is widely used for GVHD prophylaxis after allogeneic hematopoietic cell transplantation (HCT), yet its impact on cytomegalovirus (CMV) infection risk varies across subgroups...Objectives To identify patient phenotypes with differential CMV risk and heterogeneous effects of PTCy versus methotrexate (MTX)–based GVHD prophylaxis, enabling precision prophylaxis selection...In the day +100 landmark cohort, the model achieved AUC ≈ 0.76, and targeting the top 20–30% by predicted risk captured ~70% of post-day +100 CMV events, supporting risk-guided letermovir continuation and cost savings...4. Interpret clinically actionable metrics (absolute risk reduction, number needed to harm) to support evidence-based shared decision-making in HCT prophylaxis selection."
Heterogeneity • Acute Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease
|
|
Eman Elsabbagh; Augusto Dulanto Chiang; Mohammad Alexanderani; Matthew Engelhard
|